52240-70-7

Upstream product

• 586-38-9 3-Methoxybenzoic acid 
• 37951-49-8 1-(3-methoxyphenyl)propan-1-one 
• 21726-71-6 2-bromo-1-(3-methoxyphenyl)propan-1-one 
• 54961-39-6 4-(3-methoxyphenyl)-3-methyl-4-oxobutanoic acid 
• 1010800-72-2 6-(3-methoxyphenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one 

Downstream Products

• 1010801-85-0 C₂₉H₃₁F₃N₆O₄ 

Relevant academic research and scientific papers

Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration

(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl) -5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti- inflammatory agent. N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition. Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition. Both dihydropyridazinone rings, in the core and extension, can be replaced by achiral 4,4-dimethylpyrazolone subunits and the core pyrazolopyridine by isosteric bicyclic heteroaromatics. In combination, these modifications afford potent dual PDE3/4 inhibitors that suppress histamine-induced bronchoconstriction in vivo and exhibit promising anti-inflammatory activity via intratracheal administration.

PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents: and BB represents: wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.

3-(3-(3-SUBSTITUTED AMINO-2-HYDROXYPROPOXY)PHENYL)-6-HYDRAZINO PYRIDAZINES AND THEIR USE AS VASODILATORS AND BETA-ADRENERGIC BLOCKING AGENTS

The compounds are 3-(3-(3-substituted amino-2-hydroxypropoxy) phenyl)-6-hydrazino pyridazines which have β-adrenergic blocking and vasodilator activity.